Article Text

Download PDFPDF

791 Effectiveness and safety of lenvatinib and pembrolizumab (LenPem) therapy for endometrial cancer (EC): Results from a Russian multicenter database
  1. A Tyulyandina1;2,
  2. A Kedrova3;4,
  3. N Graft5,
  4. M Ibragimova6,
  5. T Krashikhina7,
  6. T Zhelezkova8,
  7. J Vasilieva8,
  8. K Maistrenko9,
  9. O Kuchevskaya9,
  10. E Markizova9,
  11. I Stradaeva10,
  12. E Markarova11,
  13. A Belonogov12,
  14. T Ibragomov13,
  15. E Zorina13,
  16. I Luev8,
  17. R Zhikhorev8,
  18. M Popova5,
  19. L Vlasova9 and
  20. M Volkonsky8
  1. 1NN Blokhin Russian Cancer Research Centre, Moscow, Russian Federation
  2. 2I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
  3. 3Federal scientific clinical center of specialized types of medical care and medical technologies, Moscow, Russian Federation
  4. 4Academy of postgraduate education under FSBU FSCC of FMBA , Moscow, Russian Federation
  5. 5Moscow Clinical Institute Scientific Center named after A. S. Loginov, Moscow, Russian Federation
  6. 6Moscow City Oncology Hospital #1, Moscow, Russian Federation
  7. 7Lyadov Clinic, Moscow, Russian Federation
  8. 8Moscow City Oncological Hospital #62, Moscow, Russian Federation
  9. 9Moscow City Clinical Hospital #40, Moscow, Russian Federation
  10. 10PET Technology Clinic, Moscow, Russian Federation
  11. 11Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
  12. 12Odintsovo Central Regional Hospital, Moscow, Russian Federation
  13. 13Podolsk oncology dispensary, Moscow, Russian Federation


Introduction/Background*The Study 111 established LenPem as a treatment option in patients with advanced endometrial cancer following prior systemic therapy. LenPem has a higher objective response rate (ORR) and progression-free survival (PFS) with a different toxicity profile. The aim of this study was to gather data regarding the efficacy and safety of LenPem when used in the real-world treatment of EC.. This is the first study to examine LenPem using (?) in EC patients treated in Russia in real practice.

Methodology Retrospective chart review identified 34 patients administred LenPem for treatment of recurrent EC in Russia from March 2020 to March 2021. Demographic and clinical data were analized.

Result(s)*Thirty-four patients (median age 66,9 years, range 57–83 years; 20,6% of patients with serous carcinoma, 82,4% ECOG ≤1, 64,7% pts with ≥2 relapses, 38,2% patients with ≥3 prior platinum-based chemotherapeutic regimens) received 1-14 cycles (median 3). In 23 patients who were examined for efficacy, the response rate (RR) was 26.2% and stabizilazion observed in 69.6% cases. Incidence of grade =>3 adverse events was similar to that in prior studies (overall 97%). The most common side effects in this study and study 111 were fatigue (64,7% and 51,1%, respectively), hypertension (47,1% and 61,7%, respectively), diarrhea (8,8% and 53,2% respectively) and stomatitis (8,8% and 35,1% respectively). Overall, 29,4% pts required dose reduction due to toxicity and in 11,8% cases required discontinuation due to disease progression.

Abstract 791 Table 1

Conclusion*Outcomes of advanced EC patients treated in Russia with LenPem following prior systemic therapy are comparable to those demonstrated in the Study 111. LEN appears to be effective and safe in real world practice in EC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.